Amino acid substitutions at sugar-recognizing codons confer ABO blood group system-related α1,3 Gal(NAc) transferases with differential enzymatic activity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 01 2019
Historique:
received: 08 08 2018
accepted: 30 11 2018
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 5 9 2020
Statut: epublish

Résumé

Functional paralogous ABO, GBGT1, A3GALT2, and GGTA1 genes encode blood group A and B transferases (AT and BT), Forssman glycolipid synthase (FS), isoglobotriaosylceramide synthase (iGb3S), and α1,3-galactosyltransferase (GT), respectively. These glycosyltransferases transfer N-acetyl-d-galactosamine (GalNAc) or d-galactose forming an α1,3-glycosidic linkage. However, their acceptor substrates are diverse. Previously, we demonstrated that the amino acids at codons 266 and 268 of human AT/BT are crucial to their distinct sugar specificities, elucidating the molecular genetic basis of the ABO glycosylation polymorphism of clinical importance in transfusion and transplantation medicine. We also prepared in vitro mutagenized ATs/BTs having any of 20 possible amino acids at those codons, and showed that those codons determine the transferase activity and sugar specificity. We have expanded structural analysis to include evolutionarily related α1,3-Gal(NAc) transferases. Eukaryotic expression constructs were prepared of AT, FS, iGb3S, and GT, possessing selected tripeptides of AT-specific AlaGlyGly or LeuGlyGly, BT-specific MetGlyAla, FS-specific GlyGlyAla, or iGb3S and GT-specific HisAlaAla, at the codons corresponding to 266-268 of human AT/BT. DNA transfection was performed using appropriate recipient cells existing and newly created, and the appearance of cell surface oligosaccharide antigens was immunologically examined. The results have shown that several tripeptides other than the originals also bestowed transferase activity. However, the repertoire of functional amino acids varied among those transferases, suggesting that structures around those codons differentially affected the interactions between donor nucleotide-sugar and acceptor substrates. It was concluded that different tripeptide sequences at the substrate-binding pocket have contributed to the generation of α1,3-Gal(NAc) transferases with diversified specificities.

Identifiants

pubmed: 30696937
doi: 10.1038/s41598-018-37515-5
pii: 10.1038/s41598-018-37515-5
pmc: PMC6351642
doi:

Substances chimiques

ABO Blood-Group System 0
Codon 0
Disaccharides 0
Galactans 0
Sugars 0
galactosyll(1,3)-N-acetylgalactosamine 0
Galactosyltransferases EC 2.4.1.-
N-acetyllactosaminide alpha-1,3-galactosyltransferase EC 2.4.1.87

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

846

Références

Eur J Biochem. 1999 Feb;259(3):770-5
pubmed: 10092863
J Biol Chem. 1999 Apr 30;274(18):12257-62
pubmed: 10212193
J Biol Chem. 1999 Oct 8;274(41):29390-8
pubmed: 10506200
Transplantation. 2000 Jan 15;69(1):187-90
pubmed: 10653403
EMBO J. 2001 Feb 15;20(4):638-49
pubmed: 11179209
J Biol Chem. 2001 Apr 27;276(17):13701-8
pubmed: 11278752
J Biol Chem. 2001 Dec 21;276(51):48608-14
pubmed: 11592969
Nat Struct Biol. 2002 Sep;9(9):685-90
pubmed: 12198488
Glycobiology. 2003 May;13(5):377-86
pubmed: 12626391
Science. 2004 Dec 3;306(5702):1786-9
pubmed: 15539565
Nature. 2005 Mar 24;434(7032):525-9
pubmed: 15791258
J Exp Med. 2006 May 15;203(5):1197-207
pubmed: 16651387
Glycobiology. 2007 May;17(5):516-28
pubmed: 17298992
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5977-82
pubmed: 17372206
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5971-6
pubmed: 17372214
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5713-4
pubmed: 17389403
J Biol Chem. 2008 Apr 11;283(15):10097-108
pubmed: 18192272
N Engl J Med. 2008 Mar 13;358(11):1109-17
pubmed: 18337601
PLoS Biol. 2008 Jul 15;6(7):e172
pubmed: 18630988
J Biol Chem. 1991 Apr 15;266(11):6991-8
pubmed: 1901859
Glycobiology. 2009 Jun;19(6):583-91
pubmed: 19218399
Hum Mol Genet. 2010 Feb 1;19(3):553-62
pubmed: 19897590
Transfusion. 2010 Mar;50(3):622-30
pubmed: 20042032
Glycobiology. 2011 Feb;21(2):162-74
pubmed: 20926599
J Biol Chem. 1990 Jan 15;265(2):1146-51
pubmed: 2104828
J Biol Chem. 1990 Apr 25;265(12):7055-61
pubmed: 2108966
J Biol Chem. 1990 Nov 5;265(31):19257-62
pubmed: 2121736
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Blood. 2013 Feb 21;121(8):1459-68
pubmed: 23255552
Nature. 1990 May 17;345(6272):229-33
pubmed: 2333095
PLoS One. 2013 Jun 14;8(6):e64728
pubmed: 23798992
Lancet. 1989 Aug 12;2(8659):358-61
pubmed: 2474731
Sci Rep. 2014 Oct 13;4:6601
pubmed: 25307962
Biochem Biophys Res Commun. 2016 Jan 29;470(1):168-174
pubmed: 26773500
Blood Transfus. 2018 Feb;16(2):178-183
pubmed: 27893352
Sci Rep. 2017 Jan 30;7:41632
pubmed: 28134301
Sci Rep. 2017 Jan 31;7:41720
pubmed: 28139731
Immunohematology. 2017 Jun;33(2):64-72
pubmed: 28657765
Sci Rep. 2017 Aug 24;7(1):9375
pubmed: 28839219
Blood Adv. 2017 Dec 20;1(27):2756-2766
pubmed: 29296927
Transfusion. 2018 Aug;58(8):2036-2045
pubmed: 30277576
Transfusion. 2018 Nov 14;:null
pubmed: 30427540
J Biol Chem. 1971 Sep 25;246(18):5766-9
pubmed: 4328838
Blood. 1979 Feb;53(2):186-92
pubmed: 570068
J Exp Med. 1984 Nov 1;160(5):1519-31
pubmed: 6491603
Jpn J Exp Med. 1981 Jun;51(3):149-55
pubmed: 7300030
J Biol Chem. 1996 May 3;271(18):10515-20
pubmed: 8631849
Mol Biol Evol. 1997 Apr;14(4):399-411
pubmed: 9100370
J Biol Chem. 1997 May 30;272(22):14133-8
pubmed: 9162041

Auteurs

Emili Cid (E)

Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.
Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut d'Investigació Germans Trias i Pujol (IGTP), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.

Miyako Yamamoto (M)

Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain.

Fumiichiro Yamamoto (F)

Laboratory of Immunohematology and Glycobiology, Josep Carreras Leukaemia Research Institute (IJC), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain. fyamamoto@carrerasresearch.org.
Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut d'Investigació Germans Trias i Pujol (IGTP), Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain. fyamamoto@carrerasresearch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH